Please assess the completion status of the following clinical trial:

Trial Title: Dry Eye Assessment and Management: Feasibility Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Sign and date the informed consent form approved by the IRB.~2. ≥ 18 years of age~3. Demonstrate at least 2 of the 4 following signs in the same eye at two consecutive visits (Visit 1: 7 - 21 days prior to randomization, and Visit 2: day of randomization).~   1. Conjunctival staining present ≥ 1~  2. Corneal fluorescein staining present ≥ 1~  3. Tear film break up time (TFBUT) ≤ 7 seconds~  4. Schirmer test ≤ 7 mm/5min~4. Demonstrate symptoms of dry eye disease (OSDI score of at least 22 at screening visit and at least 15 at randomization visit).~5. Use or desire to use artificial tears on average of 2 times per day in the 2 weeks preceding study entry (run in period). No newly diagnosed patients can be enrolled and if a new patient wants to participate, she/he must be put on tears and re-evaluated in 6 months.~6. Intraocular pressure (IOP) ≥ 5 mmHg and ≤ 22 mmHg in each eye.~7. Women of child-bearing potential must agree to use a reliable method of contraception during study participation, and must demonstrate a negative urine pregnancy test at screening visit.~8. Be willing/able to return for all study visits and to follow instructions from the study investigator and his/her staff.~9. Be able to swallow large, soft gelcaps~Exclusion Criteria:~1. Patients who are allergic to ingredients of the active or placebo pills (fish, olive oil).~2. Current diagnosis of ocular infection (e.g. bacterial, viral or fungal).~3. History of ocular herpetic keratitis.~4. Eye surgery (including cataract surgery) within 6 months prior to randomization.~5. Previous LASIK surgery~6. Pregnant or nursing/lactating~7. Participation in a study of an investigational drug or device within the past 30 days.~8. Recent (≤ 3 months) initiation of use of systemic corticosteroids or other immunosuppressive agent and/or is planning to change treatment during study participation~9. Cognitive or psychiatric deficit that precludes informed consent or ability to perform requirements of the investigation.~10. Contact lens wearers~11. Use of glaucoma medication or history of surgery for glaucoma.~12. Recent (≤ 3 months) insertion of punctual plugs.~13. Using punctual plugs but unwilling to commit to their use for the duration of the study.~14. Unwilling to commit to same brand of artificial tears throughout the study.~15. Current use of EPA/DHA supplements in excess of 1 gram/day.~16. Recent (≤ 6 months) initiation of use of Restasis.~17. Use of Restasis but unwilling to commit to use of Restasis for the duration of the study.~18. Discontinued use of Restasis within the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Omega-3 EFA Supplement (Type: EXPERIMENTAL): The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 esssential fatty acid i.e Omega-3 EFA supplement comprised of:~2000 mg EPA 1000 mg DHA
- Olive Oil (Type: PLACEBO_COMPARATOR): Gel Capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete